- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | Telomir Flat on Trial Data Release | 3 | Baystreet.ca | ||
| 07.08. | Telomir-1 hemmt Schlüsselenzyme und eröffnet neue Therapieansätze | 2 | Investing.com Deutsch | ||
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 07.08. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction | 113 | ACCESS Newswire | New data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential to treat cancer, autoimmune conditions, neurodegeneration... ► Artikel lesen | |
| 07.08. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.07. | Vielversprechende Studiendaten zur Progerie-Behandlung beflügeln Telomir-Aktie | 1 | Investing.com Deutsch | ||
| 24.07. | Telomir Pharmaceuticals stock surges on promising Progeria treatment results | 2 | Investing.com | ||
| 24.07. | Telomir-1 shows promise in restoring mitochondrial function | 2 | Investing.com | ||
| 24.07. | Telomir: Vielversprechende Studiendaten zu Telomir-1 beflügeln Aktienkurs | 5 | Investing.com Deutsch | ||
| 24.07. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to N | 171 | ACCESS Newswire | This unique cellular activity may help restore energy balance and improve essential cell functions such as protein synthesis and membrane stability in diseases like Parkinson's ALS Alzheimer's and Progeria... ► Artikel lesen | |
| 18.07. | Telomir Pharmaceuticals Stock Soars Over 90% On Positive Preclinical Data | 1 | RTTNews | ||
| 18.07. | Telomir-Aktie schießt nach vielversprechenden Daten zur Krebsbehandlung in die Höhe | 3 | Investing.com Deutsch | ||
| 18.07. | Telomir Pharmaceuticals stock soars after promising cancer treatment data | 2 | Investing.com | ||
| 18.07. | Telomir-1 shows stronger epigenetic effects than standard drugs in cancer study | 2 | Investing.com | ||
| 18.07. | Telomir Pharmaceuticals, Inc: Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin | 243 | ACCESS Newswire | New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in... ► Artikel lesen | |
| 18.07. | Telomir Pharma Skyrockets Nearly 139% After-Hours As Cancer Drug Shows Breakthrough Results, Beats Chemo In Human Cell Tests | 10 | Benzinga.com | ||
| 17.07. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 18.06. | Telomir-1 shows anti-aging effects in progeria cell study | 2 | Investing.com | ||
| 18.06. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging | 237 | ACCESS Newswire | Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals... ► Artikel lesen | |
| 18.06. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 18.06. | EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria | 2 | Benzinga.com |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 97,00 | -0,05 % | BioNTech: Hartnäckige Widerstände im Chart | Seit Monaten warten Anleger beim Mainzer Biotechnologieunternehmen auf den Befreiungsschlag. Immer wieder versuchen die Bullen, einen Aufwärtstrend zu starten, doch jeder Anstieg wurde bislang ebenso... ► Artikel lesen | |
| MODERNA | 23,910 | -0,19 % | Moderna-Aktie heute gut behauptet: Aktienwert steigt (22,935 €) | Das Wertpapier von Moderna notiert am Mittwoch etwas fester. Das Wertpapier notiert gegenwärtig bei 22,94 Euro. Für das Wertpapier von Moderna steht gegenwärtig ein Wertanstieg 4,37 Prozent zu Buche.... ► Artikel lesen | |
| VALNEVA | 4,730 | -0,76 % | Valneva: Operativer Cashburn deutlich verringert - Umsatz steigt | Valneva hat im ersten Halbjahr 2025 die Gesamterlöse um 37,8 Prozent auf 97,6 Millionen Euro gesteigert. Der Umsatz aus Produktverkäufen stieg um 33,3 Prozent auf 91 Millionen Euro. Das Unternehmen... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 51,50 | 0,00 % | Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? | ||
| BAVARIAN NORDIC | 31,720 | +0,25 % | Bavarian Nordic A/S: Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance | COPENHAGEN, Denmark, July 31, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration... ► Artikel lesen | |
| VIKING THERAPEUTICS | 34,815 | +1,77 % | The 3 Things That Matter for Viking Therapeutics Now | ||
| GERON | 1,243 | -0,08 % | Geron Corp. Posts Narrower Loss In Q1 | WASHINGTON (dpa-AFX) - Geron Corp. (GERN) posted a first quarter net loss of $19.8 million, or $0.03 per share, compared to a loss of $55.4 million, or $0.09 per share, prior year. Total net... ► Artikel lesen | |
| IMMUNITYBIO | 2,185 | +0,46 % | ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results | ||
| ZAI LAB LTD ADR | 30,400 | -0,65 % | Zai Lab Forms Oncology Advisory Board To Advance Global Cancer Therapies | ||
| VERASTEM | 7,000 | -0,71 % | Verastem stock soars after KRAS inhibitor shows strong lung cancer results | ||
| APELLIS PHARMACEUTICALS | 24,065 | +1,41 % | Apellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results | Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which... ► Artikel lesen | |
| GRAIL | 28,100 | +1,44 % | Grail war NASDAQ-Tagessieger | Der kalifornische Krebstest-Entwickler hat die vor zwei Wochen gefahrene Attacke des Shortsellers Ningi Research zunächst offenbar abgeschüttelt. Der Leerverkäufer hatte Zweifel am späteren Erfolge... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,990 | +0,12 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ANNOVIS BIO | 2,290 | -1,72 % | Annovis Bio, Inc. - 10-Q, Quarterly Report | ||
| XENON PHARMACEUTICALS | 32,000 | +0,63 % | Xenon Pharmaceuticals Inc.: Xenon Reports Second Quarter 2025 Financial Results & Business Update | - Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026- Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED... ► Artikel lesen |
TELOMIR PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,100 (-6,37 %) liegt der Kurs bei 1,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.